Key statistics
On Thursday, Apellis Pharmaceuticals Inc (APLS:NSQ) closed at 22.80, 41.61% above the 52 week low of 16.10 set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.05 |
|---|---|
| High | 22.81 |
| Low | 21.64 |
| Bid | 22.00 |
| Offer | 23.36 |
| Previous close | 22.20 |
| Average volume | 1.94m |
|---|---|
| Shares outstanding | 126.53m |
| Free float | 108.90m |
| P/E (TTM) | 74.76 |
| Market cap | 2.81bn USD |
| EPS (TTM) | 0.297 USD |
Data delayed at least 15 minutes, as of Feb 19 2026 21:00 GMT.
More ▼
- Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
- Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
- Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
- Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
- Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
- New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
More ▼
